10-Q · August 14, 2026
This 10-Q contains no revenue, EPS, cash flow, balance-sheet, margin or segment disclosures because the Company states that it conducted no significant activities beyond formation and transaction-related matters during…
OBX earnings analysis
10-Q · Filed November 12, 2026 · Our reading of the company's report
The latest report
Obsidian remains a clinical-stage biopharmaceutical company with reported EPS of -$1.23 and revenue of $0.0, while the supplied filing text does not provide the income statement, balance sheet or cash-flow detail needed…
Read full summary
Obsidian remains a clinical-stage biopharmaceutical company with reported EPS of -$1.23 and revenue of $0.0, while the supplied filing text does not provide the income statement, balance sheet or cash-flow detail needed to assess margins, working capital or free cash flow. Liquidity is a relative positive: $324.4 million of cash, cash equivalents and marketable securities is expected to fund operations into the second half of 2028, following a $350.0 million PIPE. However, the company has no approved products or product revenue, continues to face substantial clinical, regulatory and manufacturing risks, and has 29,164,045 PIPE shares registered for resale.
Reported figures
- Earnings per share
- $-1.23
What stood out
-
Liquidity extends into 2H 2028
Cash, cash equivalents and marketable securities totaled $324.4 million at September 30, 2026, which management expects to fund operating expenses and capital expenditures into the second half of 2028.
-
$350 million PIPE completed
The Concurrent PIPE Financing generated approximately $350.0 million of gross proceeds and converted into 29,164,045 shares of common stock on July 31, 2026.
-
Lead program advances clinically
Amsoki-cel is being evaluated in a Phase 2 trial for advanced melanoma and a Phase 1 trial for non-small cell lung cancer; it also has FDA Fast Track and RMAT designations for ICI-resistant unresectable or metastatic melanoma.
-
Controls assessed effective
Disclosure controls and procedures were concluded to be effective as of September 30, 2026, with no material change in internal control over financial reporting during the quarter other than changes resulting from the Mergers.
-
Oncology commercial expertise added
The board expanded from 6 to 7 directors and appointed Mark Reisenauer, who received an option for 75,364 shares at an exercise price of $13.74.
What to watch
-
No product revenue and ongoing losses
The company reported EPS of -$1.23 and revenue of $0.0 in the supplied earnings data, consistent with its stated clinical-stage profile and lack of product sales. Management expects significant losses to continue for the foreseeable future.
-
Meaningful resale and dilution risk
The 29,164,045 PIPE shares were registered for resale, and 61,774,046 common shares were outstanding as of September 30, 2026. Resales could pressure the stock price and future financings could dilute existing holders.
-
Manufacturing and BIOSECURE exposure
The company relies on third-party CDMOs and a limited number of suppliers for engineered TIL materials, viral vectors, anti-41BB and iFeeders. The BIOSECURE Act enacted on December 18, 2025 and the planned biotechnology-company-of-concern list by December 18, 2026 could restrict supplier relationships and delay clinical manufacturing.
-
Merger-related CVR obligations
The company has agreed to use commercially reasonable efforts to continue developing tilarginine for 2 years after the Mergers. CVR payments depend on receiving 80% of net proceeds before the fifth anniversary for certain agreements or before the tenth anniversary for the Supportive-Care Product Agreement; the CVRs may expire valueless.
-
Regulatory approval remains uncertain
Amsoki-cel is being pursued under a potential accelerated-approval strategy, but FDA feedback on a single-arm design is not a commitment that the design, endpoints or data will support a BLA. Accelerated approval could require a Phase 4 study and may be withdrawn if confirmatory studies fail.
-
Foreign trial data may be rejected
The company currently conducts certain trials in Australia and expects to conduct additional trials outside the United States. FDA acceptance of foreign clinical data requires the trials to be well-designed, conducted by qualified investigators and applicable to the U.S. population and medical practice.
Management's outlook
No explicit numeric revenue or EPS guidance was provided in the supplied filing text. Management states that cash, cash equivalents and marketable securities of $324.4 million as of September 30, 2026 are expected to fund operating expenses and capital expenditures into the second half of 2028.
Earlier filings 1
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.
See every OBX trade live.
The free pages stop at the last full session. Trader shows every trade as it prints.
Start tracking No card needed.